Ad blocking detected

Thank you for visiting CanadianInsider.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Club
$299/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads
JOIN THE CLUB

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

HLS Therapeutics Inc. (T:HLS)

Business Focus: Retail - Drugs without Grocery

INK Edge Outlook

Log in or join to add this stock to your watch list.

Insider Chart - Past 6 Months

Insider Filings

Latest 10 SEDI filings for HLS within the last 6 months
Loading...
See all filings within the past 6 months

Company News

Aug 08, 2019 06:30 ET
HLS Therapeutics Announces Q2 2019 Financial Results
Revenue of $13.6 million, Adjusted EBITDA of $8.1 million and Cash from Operations of $9.0 million Filed the New Drug Submission for Vascepa® with Health Canada after having been granted Priority Review status Completed a C$50.0 million (US$37.3 million) bought-deal offering In - licensed the Canadian rights to PERSERIS™, a novel long-acting injectable risperidone product for the treatment of schizophrenia Paid a quarterly dividend of C$0.05 per outstanding common share TORONTO, Aug. 8, 2019 /CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX:HLS), a specialty pharmaceutical compan
Read full article
Jul 25, 2019 06:30 ET
HLS Therapeutics to Host Q2 2019 Financial Results Conference Call
TORONTO, July 25, 2019 /CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), a specialty pharmaceutical company specializing in central nervous system and cardiovascular markets, announces that it will release its second quarter 2019 financial results by press release at 6:30 a.m. Eastern Time on Thursday, August 8, 2019. The Company will hold a conference call that same day at 8:30 a.m. Eastern Time to discuss its results. The call will be hosted by Mr. Greg Gubitz, Chief Executive Officer, Mr. Gilbert Godin, President and Chief Operating Officer and Mr. Tim Hendrickson,
Read full article
See more news stories

Valuation Ratios

Industry
Sector
Beta
-0.49
--
--
Price to Sales - TTM
5.80
4.32
2.77
Price to Book - most recent quarter
1.77
1.13
2.31
Price to Cash Flow per share - TTM
44.62
29.41
15.37
Price to Free Cash Flow per share - TTM
10.82
7.73
25.06
See all valuations

Short Report

DateNumber of Shares ShortedNet Change
Aug 15, 201942,801849
Jul 31, 201941,9521,455
Jul 15, 201940,49718,296
See Short Report

Business Summary

Sector:  Consumer Non-Cyclicals Industry:  Drug Retailers

HLS Therapeutics Inc is a Canada-based company specialized in the pharmaceutical industry. The Company acquires and distributes commercial stage and branded pharmaceutical drugs for the North American markets. The Company focuses mainly on treatment products for the central nervous system and cardiovascular specialties in Canada. Its product pipeline includes clozaril, for the treatment of schizophrenia disorders; absorica, for treatment of skin disease, such as acne; vascepa, for the treatment of hypertriglyceridemia, and trinomial for cardiovascular risk reduction. Apart from its operation in a number of regions in Canada, such as Toronto, Ontario, and Montreal, the Company also operates in the United States.

See business summary

Comment On!

140
Upload limit is up to 1mb only
To post messages to your Socail Media account, you must first give authorization from the websites. Select the platform you wish to connect your account to CanadianInsider.com (via Easy Blurb).

Twitter

Search (past week) for $HLS.CA

  • No tweets found

StockTwits